Gergely Tóth
University of Pécs
49 Papers
189 Citations
Gergely Tóth is an academic researcher from University of Pécs. The author has contributed to research in topics: Ring (chemistry) & Medicine. The author has an hindex of 6, co-authored 47 publications.
Chat about Author
Papers
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease
Lajos S. Kiss,Tamas Szamosi,T Molnár,Pál Miheller,Laszlo Lakatos,Áron Vincze,Károly Palatka,Zsolt Barta,Beáta Gasztonyi,Ágnes Salamon,Gábor Horváth,Gergely Tóth,Klaudia Farkas,János Banai,Zsolt Tulassay,Fruzsina Nagy,Mária Szenes,Gábor Veres,Barbara D. Lovasz,Zsuzsanna Vegh,Petra A. Golovics,Miklós Szathmári,Mária Papp,Peter L. Lakatos +23 more
TL;DR: Aliment Pharmacol Ther 2011; 34: 911–922; http://dx.doi.org/10.1371/journal.pbio.arsentosterone.2011.922
160
Incidence, Paris classification, and follow-up in a nationwide incident cohort of pediatric patients with inflammatory bowel disease.
Katalin Eszter Müller,Peter L. Lakatos,András Arató,Judit B. Kovács,A. Várkonyi,Dániel Szűcs,Erzsébet Szakos,Enikő Sólyom,Márta Kovács,Marianne Polgár,Éva Nemes,Ildikó Guthy,István Tokodi,Gergely Tóth,Agnes Horvath,András Tárnok,Noémi Csoszánszki,M Balogh,Noémi Vass,Piroska Bodi,Antal Dezsőfi,László Gárdos,Eva Micskey,Mária Papp,Áron Cseh,Dolóresz Szabó,Péter Vörös,Gábor Veres +27 more
TL;DR: The incidence of pediatric IBD in Hungary was among the higher range reported, and the first large, nationwide incident cohort analyzed according to the Paris classification, which is a useful tool to determine the characteristic pediatric CD phenotype.
Baseline Characteristics and Disease Phenotype in Inflammatory Bowel Disease.
Katalin Eszter Müller,Peter L. Lakatos,Judit B. Kovács,András Arató,A. Várkonyi,Éva Nemes,András Tárnok,Gergely Tóth,Mária Papp,Enikő Sólyom,Agnes Horvath,Ildikó Guthy,Márta Kovács,Gábor Veres +13 more
TL;DR: At diagnosis, half of the patients with IBD had moderate-to-severe disease, and this rate decreased to <10% after 1 year, and initial CRP and PCDAI were related to the need for aggressive therapy in CD.
•Journal Article
Characterization of degradation products of mometasone furoate.
TL;DR: The instability of MF in SLF resulted in two degradation products, one of the degradation products showing glucocorticoid receptor activity, the other representing a new cyclized structure whose pharmacological properties have not been described.
12